Next-generation sequencing for diagnosis of thoracic aortic aneurysms and dissections: diagnostic yield, novel mutations and genotype phenotype correlations

J K Poninska, Z T Bilinska, M Franaszczyk, E Michalak, M Rydzanicz, E Szpakowski, A Pollak, B Milanowska, G Truszkowska, P Chmielewski, A Sioma, H Janaszek-Sitkowska, A Klisiewicz, I Michalowska, M Makowiecka-Ciesla, P Kolsut, P Stawinski, B Foss-Nieradko, M Szperl, J Grzybowski, P Hoffman, A Januszewicz, M Kusmierczyk, R Ploski, J K Poninska, Z T Bilinska, M Franaszczyk, E Michalak, M Rydzanicz, E Szpakowski, A Pollak, B Milanowska, G Truszkowska, P Chmielewski, A Sioma, H Janaszek-Sitkowska, A Klisiewicz, I Michalowska, M Makowiecka-Ciesla, P Kolsut, P Stawinski, B Foss-Nieradko, M Szperl, J Grzybowski, P Hoffman, A Januszewicz, M Kusmierczyk, R Ploski

Abstract

Background: Thoracic aortic aneurysms and dissections (TAAD) are silent but possibly lethal condition with up to 40 % of cases being hereditary. Genetic background is heterogeneous. Recently next-generation sequencing enabled efficient and cost-effective examination of gene panels. Aim of the study was to define the diagnostic yield of NGS in the 51 TAAD patients and to look for genotype-phenotype correlations within families of the patients with TAAD.

Methods: 51 unrelated TAAD patients were examined by either whole exome sequencing or TruSight One sequencing panel. We analyzed rare variants in 10 established thoracic aortic aneurysms-associated genes. Whenever possible, we looked for co-segregation in the families. Kaplan-Meier survival curve was constructed to compare the event-free survival depending on genotype. Aortic events were defined as acute aortic dissection or first planned aortic surgery.

Results and discussion: In 21 TAAD patients we found 22 rare variants, 6 (27.3 %) of these were previously reported, and 16 (73.7 %) were novel. Based on segregation data, functional analysis and software estimations we assumed that three of novel variants were causative, nine likely causative. Remaining four were classified as of unknown significance (2) and likely benign (2). In all, 9 (17.6 %) of 51 probands had a positive result when considering variants classified as causative only and 18 (35.3 %) if likely causative were also included. Genotype-positive probands (n = 18) showed shorter mean event free survival (41 years, CI 35-46) than reference group, i.e. those (n = 29) without any plausible variant identified (51 years, CI 45-57, p = 0.0083). This effect was also found when the 'genotype-positive' group was restricted to probands with 'likely causative' variants (p = 0.0092) which further supports pathogenicity of these variants. The mean event free survival was particularly low (37 years, CI 27-47) among the probands with defects in the TGF beta signaling (p = 0.0033 vs. the reference group).

Conclusions: This study broadens the spectrum of genetic background of thoracic aneurysms and dissections and supports its potential role as a prognostic factor in the patients with the disease.

Keywords: Diagnosis; Loeys–Dietz syndrome; Marfan syndrome; Next-generation sequencing; Shprintzen–Goldberg syndrome; Thoracic aortic aneurysm and dissections.

Figures

Fig. 1
Fig. 1
Pedigrees of families with fibrillinopathies
Fig. 2
Fig. 2
Pedigrees of families with mutations in ACTA2, COL3A1, TGFBR1, MYH11, SKI, SMAD3, TGFBR1 and TGFBR2 genes
Fig. 3
Fig. 3
Kaplan–Meier analysis of event free survival in TAAD in probands with variants classified as causative/likely causative vs. those without any candidate variants identified (Log-Rank Chi- square 6.97, p = 0.0083)
Fig. 4
Fig. 4
Cardiovascular imaging study in the patient with SKI p.T20 K variant. a 2D transthoracic echocardiography of parasternal long axis demonstrated aortic root aneurysm with Valsalva sinuses diameter of 48.5 mm.; b and d 2D transthoracic echocardiography in apical four chamber view in diastole. Enlarged left ventricle and left atrium with increased mitral annular diameter of 51.4 mm; c contrast-enhanced, ECG-gated CT, volume rendering (VR) image, the aneurysm of the ascending aorta; d color flow Doppler study revealed significant mitral regurgitation due to thickened and floppy mitral valve leaflets and widened mitral annulus
Fig. 5
Fig. 5
Cardiovascular imaging study in the patient with MYH11 p.E1840D variant. a contrast-enhanced, ECG-gated CT, multiplanar reformatted image with reconstruction parallel to aortic valve shows bicuspid aortic valve in diastole; b volume rendering (VR) image, the aneurysm of the thoracic aorta: root of 43 mm, ascending aorta- of 52 mm (maximum dimension) and aorta before the origin of brachiocephalic trunk of 40 mm, farther arch dimension is normal of 28 mm
Fig. 6
Fig. 6
Cardiovascular imaging study in the patient with MYH11 p.R1758Q variant. a contrast-enhanced, ECG-gate CT, multiplanar reformatted images with reconstruction parallel to aortic valve show bicuspid aortic valve in diastole; b volume rendering (VR) image shows supracoronary prosthesis and dilated aortic arch. Variant anatomy: common origin of brachiocephalic and left common carotid artery. Aortic arch diameter before the anomaly of 42 mm

References

    1. Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey DE, Jr, et al. ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation. 2010;121(13):e266–e369. doi: 10.1161/CIR.0b013e3181d4739e.
    1. Elefteriades JA, Farkas EA. Thoracic aortic aneurysm clinically pertinent controversies and uncertainties. J Am Coll Cardiol. 2010;55(9):841–857. doi: 10.1016/j.jacc.2009.08.084.
    1. Albornoz G, Coady MA, Roberts M, Davies RR, Tranquilli M, Rizzo JA, et al. Familial thoracic aortic aneurysms and dissections–incidence, modes of inheritance, and phenotypic patterns. Ann Thorac Surg. 2006;82(4):1400–1405. doi: 10.1016/j.athoracsur.2006.04.098.
    1. Disabella E, Grasso M, Gambarin FI, Narula N, Dore R, Favalli V, et al. Risk of dissection in thoracic aneurysms associated with mutations of smooth muscle alpha-actin 2 (ACTA2) Heart. 2011;97(4):321–326. doi: 10.1136/hrt.2010.204388.
    1. Milewicz DM, Carlson AA, Regalado ES. Genetic testing in aortic aneurysm disease: PRO. Cardiol Clin. 2010;28(2):191–197. doi: 10.1016/j.ccl.2010.01.017.
    1. Lee B, Godfrey M, Vitale E, Hori H, Mattei MG, Sarfarazi M, et al. Linkage of Marfan syndrome and a phenotypically related disorder to two different fibrillin genes. Nature. 1991;352(6333):330–334. doi: 10.1038/352330a0.
    1. Maslen CL, Corson GM, Maddox BK, Glanville RW, Sakai LY. Partial sequence of a candidate gene for the Marfan syndrome. Nature. 1991;352(6333):334–337. doi: 10.1038/352334a0.
    1. Dietz HC, Cutting GR, Pyeritz RE, Maslen CL, Sakai LY, Corson GM, et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature. 1991;352(6333):337–339. doi: 10.1038/352337a0.
    1. Kroes HY, Pals G, van Essen AJ. Ehlers-Danlos syndrome type IV: unusual congenital anomalies in a mother and son with a COL3A1 mutation and a normal collagen III protein profile. Clin Genet. 2003;63(3):224–227. doi: 10.1034/j.1399-0004.2003.00047.x.
    1. Mizuguchi T, Collod-Beroud G, Akiyama T, Abifadel M, Harada N, Morisaki T, et al. Heterozygous TGFBR2 mutations in Marfan syndrome. Nat Genet. 2004;36(8):855–860. doi: 10.1038/ng1392.
    1. Loeys BL, Chen J, Neptune ER, Judge DP, Podowski M, Holm T, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet. 2005;37(3):275–281. doi: 10.1038/ng1511.
    1. Zhu L, Vranckx R, Khau Van Kien P, Lalande A, Boisset N, Mathieu F, et al. Mutations in myosin heavy chain 11 cause a syndrome associating thoracic aortic aneurysm/aortic dissection and patent ductus arteriosus. Nat Genet. 2006;38(3):343–349. doi: 10.1038/ng1721.
    1. Guo DC, Pannu H, Tran-Fadulu V, Papke CL, Yu RK, Avidan N, et al. Mutations in smooth muscle alpha-actin (ACTA2) lead to thoracic aortic aneurysms and dissections. Nat Genet. 2007;39(12):1488–1493. doi: 10.1038/ng.2007.6.
    1. Loeys BL, Dietz HC, Braverman AC, Callewaert BL, De Backer J, Devereux RB, et al. The revised Ghent nosology for the Marfan syndrome. J Med Genet. 2010;47(7):476–485. doi: 10.1136/jmg.2009.072785.
    1. Greally MT. Shprintzen–Goldberg Syndrome. 1993. doi: NBK1277 [bookaccession].
    1. Freed LA, Benjamin EJ, Levy D, Larson MG, Evans JC, Fuller DL, et al. Mitral valve prolapse in the general population: the benign nature of echocardiographic features in the Framingham Heart Study. J Am Coll Cardiol. 2002;40(7):1298–1304. doi: 10.1016/S0735-1097(02)02161-7.
    1. Ploski R, Pollak A, Muller S, Franaszczyk M, Michalak E, Kosinska J, et al. Does p. Q247X in TRIM63 cause human hypertrophic cardiomyopathy? Circ Res. 2014;114(2):e2–e5. doi: 10.1161/CIRCRESAHA.114.302662.
    1. Naz S, Fatima A. Amplification of GC-rich DNA for high-throughput family-based genetic studies. Mol Biotechnol. 2013;53(3):345–350. doi: 10.1007/s12033-012-9559-y.
    1. Wooderchak-Donahue W, VanSant-Webb C, Tvrdik T, Plant P, Lewis T, Stocks J, et al. Clinical utility of a next generation sequencing panel assay for Marfan and Marfan-like syndromes featuring aortopathy. Am J Med Genet A. 2015;167A(8):1747–1757. doi: 10.1002/ajmg.a.37085.
    1. Proost D, Vandeweyer G, Meester JA, Salemink S, Kempers M, Ingram C, et al. Performant mutation identification using targeted next-generation sequencing of 14 thoracic aortic aneurysm genes. Hum Mutat. 2015;36(8):808–814. doi: 10.1002/humu.22802.
    1. Ziganshin BA, Bailey AE, Coons C, Dykas D, Charilaou P, Tanriverdi LH, et al. Routine genetic testing for thoracic aortic aneurysm and dissection in a clinical setting. Ann Thorac Surg. 2015;100(5):1604–1611. doi: 10.1016/j.athoracsur.2015.04.106.
    1. Tiecke F, Katzke S, Booms P, Robinson PN, Neumann L, Godfrey M, et al. Classic, atypically severe and neonatal Marfan syndrome: twelve mutations and genotype-phenotype correlations in FBN1 exons 24-40. Eur J Hum Genet. 2001;9(1):13–21. doi: 10.1038/sj.ejhg.5200582.
    1. Yoo EH, Woo H, Ki CS, Lee HJ, Kim DK, Kang IS, et al. Clinical and genetic analysis of Korean patients with Marfan syndrome: possible ethnic differences in clinical manifestation. Clin Genet. 2010;77(2):177–182. doi: 10.1111/j.1399-0004.2009.01287.x.
    1. Stheneur C, Collod-Beroud G, Faivre L, Buyck JF, Gouya L, Le Parc JM, et al. Identification of the minimal combination of clinical features in probands for efficient mutation detection in the FBN1 gene. Eur J Hum Genet. 2009;17(9):1121–1128. doi: 10.1038/ejhg.2009.36.
    1. Aalberts JJ, van Tintelen JP, Meijboom LJ, Polko A, Jongbloed JD, van der Wal H, et al. Relation between genotype and left-ventricular dilatation in patients with Marfan syndrome. Gene. 2014;534(1):40–43. doi: 10.1016/j.gene.2013.10.033.
    1. Ogawa N, Imai Y, Takahashi Y, Nawata K, Hara K, Nishimura H, et al. Evaluating Japanese patients with the Marfan syndrome using high-throughput microarray-based mutational analysis of fibrillin-1 gene. Am J Cardiol. 2011;108(12):1801–1807. doi: 10.1016/j.amjcard.2011.07.053.
    1. Loeys B, Nuytinck L, Delvaux I, De Bie S, De Paepe A. Genotype and phenotype analysis of 171 patients referred for molecular study of the fibrillin-1 gene FBN1 because of suspected Marfan syndrome. Arch Intern Med. 2001;161(20):2447–2454. doi: 10.1001/archinte.161.20.2447.
    1. Collod-Beroud G, Le Bourdelles S, Ades L, Ala-Kokko L, Booms P, Boxer M, et al. Update of the UMD-FBN1 mutation database and creation of an FBN1 polymorphism database. Hum Mutat. 2003;22(3):199–208. doi: 10.1002/humu.10249.
    1. Comeglio P, Johnson P, Arno G, Brice G, Evans A, Aragon-Martin J, et al. The importance of mutation detection in Marfan syndrome and Marfan-related disorders: report of 193 FBN1 mutations. Hum Mutat. 2007;28(9):928. doi: 10.1002/humu.9505.
    1. Howarth R, Yearwood C, Harvey JF. Application of dHPLC for mutation detection of the fibrillin-1 gene for the diagnosis of Marfan syndrome in a National Health Service Laboratory. Genet Test. 2007;11(2):146–152. doi: 10.1089/gte.2006.0514.
    1. Soylen B, Singh KK, Abuzainin A, Rommel K, Becker H, Arslan-Kirchner M, et al. Prevalence of dural ectasia in 63 gene-mutation-positive patients with features of Marfan syndrome type 1 and Loeys-Dietz syndrome and report of 22 novel FBN1 mutations. Clin Genet. 2009;75(3):265–270. doi: 10.1111/j.1399-0004.2008.01126.x.
    1. Waldmuller S, Muller M, Warnecke H, Rees W, Schols W, Walterbusch G, et al. Genetic testing in patients with aortic aneurysms/dissections: a novel genotype/phenotype correlation? Eur J Cardiothorac Surg. 2007;31(6):970–975. doi: 10.1016/j.ejcts.2007.02.027.
    1. Faivre L, Gorlin RJ, Wirtz MK, Godfrey M, Dagoneau N, Samples JR, et al. In frame fibrillin-1 gene deletion in autosomal dominant Weill-Marchesani syndrome. J Med Genet. 2003;40(1):34–36. doi: 10.1136/jmg.40.1.34.
    1. Matyas G, De Paepe A, Halliday D, Boileau C, Pals G, Steinmann B. Evaluation and application of denaturing HPLC for mutation detection in Marfan syndrome: identification of 20 novel mutations and two novel polymorphisms in the FBN1 gene. Hum Mutat. 2002;19(4):443–456. doi: 10.1002/humu.10054.
    1. Robinson DO, Lin F, Lyon M, Raponi M, Cross E, White HE, et al. Systematic screening of FBN1 gene unclassified missense variants for splice abnormalities. Clin Genet. 2012;82(3):223–231. doi: 10.1111/j.1399-0004.2011.01781.x.
    1. Attanasio M, Pratelli E, Porciani MC, Evangelisti L, Torricelli E, Pellicano G, et al. Dural ectasia and FBN1 mutation screening of 40 patients with Marfan syndrome and related disorders: role of dural ectasia for the diagnosis. Eur J Med Genet. 2013;56(7):356–360. doi: 10.1016/j.ejmg.2013.04.006.
    1. Aalberts JJ, Schuurman AG, Pals G, Hamel BJ, Bosman G, Hilhorst-Hofstee Y, et al. Recurrent and founder mutations in the Netherlands: extensive clinical variability in Marfan syndrome patients with a single novel recurrent fibrillin-1 missense mutation. Neth Heart J. 2010;18(2):85–89. doi: 10.1007/BF03091743.
    1. Grau U, Klein HG, Detter C, Mair H, Welz A, Seidel D, et al. A novel mutation in the neonatal region of the fibrillin (FBN)1 gene associated with a classical phenotype of Marfan syndrome (MfS). Mutations in brief no. 163. Online. Hum Mutat. 1998;12(2):137. doi: 10.1002/(SICI)1098-1004(1998)12:2<137::AID-HUMU14>;2-P.
    1. Arslan-Kirchner M, Epplen JT, Faivre L, Jondeau G, Schmidtke J, De Paepe A et al. Clinical utility gene card for: Loeys-Dietz syndrome (TGFBR1/2) and related phenotypes. Eur J Hum Genet. 2011;19(10). doi:10.1038/ejhg.2011.68.
    1. Frischmeyer-Guerrerio PA, Guerrerio AL, Oswald G, Chichester K, Myers L, Halushka MK et al. TGFbeta receptor mutations impose a strong predisposition for human allergic disease. Sci Transl Med. 2013;5(195):195ra94. doi:10.1126/scitranslmed.3006448.
    1. Schepers D, Doyle AJ, Oswald G, Sparks E, Myers L, Willems PJ, et al. The SMAD-binding domain of SKI: a hotspot for de novo mutations causing Shprintzen-Goldberg syndrome. Eur J Hum Genet. 2015;23(2):224–228. doi: 10.1038/ejhg.2014.61.
    1. van de Laar IM, Oldenburg RA, Pals G, Roos-Hesselink JW, de Graaf BM, Verhagen JM, et al. Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis. Nat Genet. 2011;43(2):121–126. doi: 10.1038/ng.744.
    1. van de Laar IM, van der Linde D, Oei EH, Bos PK, Bessems JH, Bierma-Zeinstra SM, et al. Phenotypic spectrum of the SMAD3-related aneurysms-osteoarthritis syndrome. J Med Genet. 2012;49(1):47–57. doi: 10.1136/jmedgenet-2011-100382.
    1. Harakalova M, van der Smagt J, de Kovel CG, Van’t Slot R, Poot M, Nijman IJ, et al. Incomplete segregation of MYH11 variants with thoracic aortic aneurysms and dissections and patent ductus arteriosus. Eur J Hum Genet. 2013;21(5):487–493. doi: 10.1038/ejhg.2012.206.
    1. Guo DC, Papke CL, Tran-Fadulu V, Regalado ES, Avidan N, Johnson RJ, et al. Mutations in smooth muscle alpha-actin (ACTA2) cause coronary artery disease, stroke, and Moyamoya disease, along with thoracic aortic disease. Am J Hum Genet. 2009;84(5):617–627. doi: 10.1016/j.ajhg.2009.04.007.
    1. Henkel W. Cross-link analysis of the C-telopeptide domain from type III collagen. Biochem J. 1996;318(Pt 2):497–503. doi: 10.1042/bj3180497.
    1. Morissette R, Schoenhoff F, Xu Z, Shilane DA, Griswold BF, Chen W, et al. Transforming growth factor-beta and inflammation in vascular (type IV) Ehlers-Danlos syndrome. Circ Cardiovasc Genet. 2014;7(1):80–88. doi: 10.1161/CIRCGENETICS.113.000280.
    1. Liu WO, Oefner PJ, Qian C, Odom RS, Francke U. Denaturing HPLC-identified novel FBN1 mutations, polymorphisms, and sequence variants in Marfan syndrome and related connective tissue disorders. Genet Test. 1997;1(4):237–242. doi: 10.1089/gte.1997.1.237.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi